The controlled usage of veterinary drugs is a necessity not only for the wellbeing of the animals but also for the quality and safety of human food. The diclazuril is among the commonly administered anticoccidials in veterinary medicine for combating avian coccidiosis, which may lead to its accumulation in poultry's tissues and consequently may possess potential hazards on human consumer's health. Accordingly, this trial was designed to detect residues of diclazuril in different broiler tissues and to define its withdrawal period to ensure the safety for human consumption. A total of 150 broiler chicks of one day old were grouped into several groups; Group II: was orally gavage diclazuril at a dose rate of 0.3 mg/kg bodyweight once daily for 3 successive days only at age of 15 th day old, group III: was orally gavage the same dose once daily for 3 successive days at age of 15 th day old and for another 3 successive days at age of 32 nd , finally group IV: was orally gavage the same dose once daily for 3 successive days only at age of 32 nd day old. One day post last diclazuril administration and for 7 successive days, five chicks were slaughtered daily from all treated groups and samples from muscle, liver and kidney were obtained to be analyzed by high performance liquid chromatography (HPLC). Diclazuril was detected in muscles, kidney and liver of all treated groups. Whereas the detected concentrations were below the permissible limits, so it was concluded that there is no premarketing withdrawal requirement for diclazuril. Also neither the age of the bird, nor the repeated doses of diclazuril with time interval affected the accumulation of the diclazuril in broiler tissues. Further studies needed to monitor the effect of longer administration period of diclazuril on its accumulation in different broiler tissues.